Small Molecule API process development: Process development and analytical support from preclinical all the way through commercial manufacturing.   
Small Molecule formulation development and manufacturing: Integrated drug product platform, from pre-formulation to commercial manufacturing, including solid-state development, developability and formulation research, formulation development, and Clinical Trial Material (CTM), and commercial manufacturing in various oral and injectable dosage forms.
Oligonucleotide and peptide discovery: Delivering oligonucleotide and peptide medicinal chemistry solutions for creating, identifying, and supporting the discovery of preclinical candidates (PCC’s) with our enabling discovery chemistry platform.
Oligonucleotide and peptide pre-formulation and formulation: Parenteral oligonucleotide and peptide drug pre-formulation and formulation development, lipid nanoparticle formulation development.
Tianjin site has started to operate in 2007, currently it has 18.6 acres of synthetic and analytical state-of-the-art R&D lab.
Small molecule process development & analytical services: provide services including discovery chemistry, library synthesis and discovery process chemistry (DPC), establish capability platforms like flow chemistry, biotransformation, electrochemistry, photochemistry, crystallization platform and catalysis screening etc.
Oligonucleotide discovery: deliver oligonucleotide medicinal chemistry solutions for creating, identifying, and supporting the discovery of preclinical candidates (PCC’s) with our discovery chemistry platform.
Amidite and GalNAc: One-stop solution including custom synthesis solutions for various amidite and GalNAc molecules, oligonucleotides, as well as a broad range of oligonucleotide-based conjugates. 300+ catalog amidite products are available to accelerate your oligonucleotide therapeutic development.
Wuhan site has started to operate in 2012, currently it has 28.8 acres of synthetic and analytical state-of-the-art R&D lab.
Peptide discovery: deliver peptide medicinal chemistry solutions for creating, identifying, and supporting the discovery of preclinical candidates (PCC’s) with our discovery chemistry platform.
Chengdu R&D center is in Chengdu Medical City and has been in operation since August 2020, with a total construction area of about 24.7 acres. 
Unnatural amino acid synthesis: Provide custom synthesis solutions for unnatural amino acids and other peptide related building blocks. 2,200+ catalog unnatural amino acid products are available to accelerate your peptide therapeutic development.
This 74-acre fully integrated R&D and cGMP manufacturing campus currently includes 2 R&D center, 15 plants. Changzhou is about 1-hour driving distance (75 km) to Wuxi city (drug product site) which enables seamless collaborations between API team and formulation team for efficient, flexible, and high-quality solutions to global pharma and biotech customers.
Small molecule, oligonucleotide & peptide API process development and manufacturing: Changzhou site is a fully integrated R&D and manufacturing campus providing a unique one-site solution for APIs and advanced intermediates, including small molecule, HPAPI, oligonucleotide, peptide, and related synthetic conjugates, through preclinical and clinical development to global commercial launch.
Changzhou site has successfully passed inspections by US FDA and China NMPA multiple times since 2018.
The Jinshan site is an integrated API process R&D and commercial manufacturing campus, including one R&D center, 5 API manufacturing plants, high potency R&D labs & plants, and one enzyme fermentation plant.
The site is enabled for high-tech manufacturing processing including large scale chromatography, continuous processing (flow chemistry), and biocatalysis.
This site offers turnkey process R&D, API, and drug product manufacturing services for early-phase clinical studies, equipped with a cGMP pilot plant, cGMP kilo lab with 6 production bays as well as process chemistry and analytical labs.
The Wuxi city site is an integrated drug product R&D and manufacturing campus, including 1 R&D center, 3 oral solid plants, 1 parenteral plant and QC labs. Wuxi city is about 1-hour driving distance (75 km) to Changzhou (Small molecule, Oligonucleotide and peptide API process R&D and manufacturing site) which enables seamless collaborations between API team and formulation team for efficient, flexible, and high-quality solutions to global pharma and biotech customers.
Oral solid formulation development and manufacturing: 1 oral solid clinical-scale plant and 2 oral solid commercial-scale plants provide manufacturing, packaging, and labeling services supporting both tablet and capsule dosage forms.
Parenteral formulation development and manufacturing: Parenteral small molecule, oligonucleotide, and peptide formulation development as well as analytical testing and QC platform. Parenteral formulation manufacturing lines feature a fully enclosed isolator supporting various of dosage forms including solution, emulsion, suspension, and lyophilized powder with different filling format including vial, pre-filled syringe, and cartridge.
Lipid nanoparticle formulation development and manufacturing: LNP platform features multi-channel mixing technology for robust scalability and reproducibility with integrated formulation development, analytical, in vitro/ in vivo evaluation. GMP manufacturing line is fully validated and in use.
Wuxi city site has successfully passed inspections by US FDA, EMA, and China NMPA multiple times since 2021.
It is newly constructed in 2016-2018, designed with industry-leading energy efficiency and environmental standards and has been inspected by US FDA, Japan PMDA, and SwissMedic in 2018-2023.
The Couvet site is equipped with a manufacturing plant, a GMP warehouse as well as quality control labs. This site offers commercial drug product manufacturing and packaging for capsule and tablet dosage forms and supports bottle & blister packaging. Click to view Couvet Site video
Coming soon. It is a new 50-acre API process R&D and manufacturing site in Singapore. Phase I includes a large-scale manufacturing plant for oligonucleotides, peptides, and the related synthetic conjugates and 2 plants for small molecule API, expected to start operation in 2026.
Coming soon. The phase I of this 190-acre new facility is designed for formulation development and manufacture including packaging, labeling and distribution for oral and parenteral drug products including oligonucleotides, peptides and the related synthetic conjugates, expected to start operation in 2026.